Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
April 13, 2015
Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma
Jordan A Torok, Yuan Wu, Leonard R Prosnitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2007
Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab
Jesús G Berdeja, Allan Hess, David M Lucas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2005
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia
Yvette L Kasamon, Ian W Flinn, Michael R Grever, et al.
Annals of Hematology
|
March 7, 2006
A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma
Carl R Willis, Amy Goodrich, Kathy Park, et al.
Leukemia Research
|
October 11, 2012
Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia
Tod A Morris, Carlos M DeCastro, Louis F Diehl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 31, 2004
Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma
Yvette L Kasamon, Richard J Jones, Louis F Diehl, et al.
Cancer Investigation
|
February 15, 2013
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma
Lauren A Held, David Rizzieri, Gwynn D Long, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse
Anjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2009
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia
Daphne R Friedman, J Brice Weinberg, William T Barry, et al.
Leukemia & Lymphoma
|
August 11, 2011
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia
Mark C Lanasa, Patricia H Davis, Michael Datto, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
International Journal of Radiation Oncology, Biology, Physics
|
April 13, 2015
Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma
Jordan A Torok, Yuan Wu, Leonard R Prosnitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2007
Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab
Jesús G Berdeja, Allan Hess, David M Lucas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2005
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia
Yvette L Kasamon, Ian W Flinn, Michael R Grever, et al.
Annals of Hematology
|
March 7, 2006
A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma
Carl R Willis, Amy Goodrich, Kathy Park, et al.
Leukemia Research
|
October 11, 2012
Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia
Tod A Morris, Carlos M DeCastro, Louis F Diehl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 31, 2004
Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma
Yvette L Kasamon, Richard J Jones, Louis F Diehl, et al.
Cancer Investigation
|
February 15, 2013
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma
Lauren A Held, David Rizzieri, Gwynn D Long, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse
Anjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2009
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia
Daphne R Friedman, J Brice Weinberg, William T Barry, et al.
Leukemia & Lymphoma
|
August 11, 2011
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia
Mark C Lanasa, Patricia H Davis, Michael Datto, et al.
Page
of 3